Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03662100 · ClinicalTrials.gov registry record · Phase 1
A Study of Two Formulations of LY3074828 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
NCT03662100 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 66 participants.
The verdict
NCT03662100, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
Study Summary
The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects experienced will be collected. Screening is required within 28 days prior to the start of the study. For each participant, the study will last about 12 weeks, not including screening.
Interventions
- DRUG LY3074828
- BIOLOGICAL LY3074828
- DEVICE Auto-injector (AI)
- DEVICE Prefilled syringe (PFS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2018-09-06 |
| Est. Completion | 2019-01-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03662100
The ClinicalTrials.gov registry entry for NCT03662100 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which LY3074828 is the first listed.
NCT03662100 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03662100 about?
NCT03662100 is a clinical study titled "A Study of Two Formulations of LY3074828 in Healthy Participants". The purpose of this study is to look at the amount of the study drug, LY3074828, that gets into the blood stream and how long it takes the body to get rid of LY3074828 when given as different formulations. The tolerability of LY3074828 will also be evaluated and information about any side effects ex...
What is the current status of trial NCT03662100?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2018-09-06. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT03662100?
The interventions under investigation include: LY3074828 (DRUG), LY3074828 (BIOLOGICAL), Auto-injector (AI) (DEVICE), Prefilled syringe (PFS) (DEVICE).
Who is sponsoring clinical trial NCT03662100?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.